Trial Profile
A Phase I study of setmelanotide FluidCrystal for the treatment of life-threatening obesity due to rare and serious genetic disorders.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2017
Price :
$35
*
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacokinetics
- 26 Oct 2017 According to a Camurus media release, final results from this trial are expected in Q4 2017.
- 27 Jun 2017 Initial results published in a joint media release by Rhythm and Camarus.
- 07 Jan 2016 New trial record